X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Procter & Gamble Health with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs NATCO PHARMA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH NATCO PHARMA PROCTER & GAMBLE HEALTH/
NATCO PHARMA
 
P/E (TTM) x 53.0 15.0 353.6% View Chart
P/BV x 4.8 2.9 162.9% View Chart
Dividend Yield % 9.9 1.5 653.1%  

Financials

 PROCTER & GAMBLE HEALTH   NATCO PHARMA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
NATCO PHARMA
Mar-18
PROCTER & GAMBLE HEALTH/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,5491,080 328.6%   
Low Rs1,301671 193.8%   
Sales per share (Unadj.) Rs511.4592.1 86.4%  
Earnings per share (Unadj.) Rs61.3188.4 32.5%  
Cash flow per share (Unadj.) Rs74.0206.3 35.9%  
Dividends per share (Unadj.) Rs440.008.25 5,333.3%  
Dividend yield (eoy) %18.10.9 1,925.7%  
Book value per share (Unadj.) Rs927.8833.6 111.3%  
Shares outstanding (eoy) m16.6036.90 45.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.71.5 320.6%   
Avg P/E ratio x39.64.6 851.3%  
P/CF ratio (eoy) x32.84.2 772.1%  
Price / Book Value ratio x2.61.1 248.8%  
Dividend payout %717.94.4 16,394.5%   
Avg Mkt Cap Rs m40,25732,311 124.6%   
No. of employees `0001.14.8 23.5%   
Total wages/salary Rs m1,3133,256 40.3%   
Avg. sales/employee Rs Th7,486.74,522.5 165.5%   
Avg. wages/employee Rs Th1,157.6674.0 171.8%   
Avg. net profit/employee Rs Th897.21,439.0 62.3%   
INCOME DATA
Net Sales Rs m8,49021,848 38.9%  
Other income Rs m244404 60.4%   
Total revenues Rs m8,73422,252 39.2%   
Gross profit Rs m1,4829,284 16.0%  
Depreciation Rs m211662 31.9%   
Interest Rs m0154 0.0%   
Profit before tax Rs m1,5148,872 17.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m5631,920 29.3%   
Profit after tax Rs m1,0176,952 14.6%  
Gross profit margin %17.542.5 41.1%  
Effective tax rate %37.121.6 171.6%   
Net profit margin %12.031.8 37.7%  
BALANCE SHEET DATA
Current assets Rs m15,34321,307 72.0%   
Current liabilities Rs m1,9605,920 33.1%   
Net working cap to sales %157.670.4 223.8%  
Current ratio x7.83.6 217.5%  
Inventory Days Days4973 66.5%  
Debtors Days Days28107 26.7%  
Net fixed assets Rs m1,20914,986 8.1%   
Share capital Rs m166369 45.0%   
"Free" reserves Rs m15,23530,353 50.2%   
Net worth Rs m15,40130,760 50.1%   
Long term debt Rs m00-   
Total assets Rs m17,59537,151 47.4%  
Interest coverage xNM58.6-  
Debt to equity ratio x00-  
Sales to assets ratio x0.50.6 82.1%   
Return on assets %5.819.1 30.2%  
Return on equity %6.622.6 29.2%  
Return on capital %10.329.3 35.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63610,322 15.9%   
Fx outflow Rs m4,3682,978 146.7%   
Net fx Rs m-2,7327,343 -37.2%   
CASH FLOW
From Operations Rs m-1,3044,636 -28.1%  
From Investments Rs m12,697-11,155 -113.8%  
From Financial Activity Rs m-3016,509 -4.6%  
Net Cashflow Rs m11,093-18 -61,627.2%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 51.8 1.5 3,523.8%  
Indian inst/Mut Fund % 18.2 7.8 232.1%  
FIIs % 1.0 16.6 6.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 26.0 111.9%  
Shareholders   28,591 25,395 112.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   NOVARTIS  TORRENT PHARMA  STRIDES PHARMA SCIENCE  CIPLA  ASTRAZENECA PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Realty and Metal Stocks Lag(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.1% while the Hang Seng is flat.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

The Perfect Stock in the Rebirth of India(The 5 Minute Wrapup)

Aug 8, 2019

This debt-free, well-managed company is all set to soar.

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too(The 5 Minute Wrapup)

Aug 9, 2019

Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Aug 21, 2019 10:03 AM

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS